

# THC Global Group Ltd

10:15 22 Apr 2020

## THC Global's Australian produced medicinal cannabis available for prescription next month

THC Global Group Ltd's (ASX:THC) first Candeo branded medicinal cannabis medicines produced in Australia will be available for prescription from May 20, 2020.

The company's medicinal cannabis medicines, which use Australian cannabis plant material, are manufactured at its Southport pharmaceuticals GMP facility.

Chief executive officer Ken Charteris said: "We will be able to offer our Australian produced, high-quality medicinal cannabis medicines under the Candeo brand for prescription to Australian patients.

"These medicines will be more affordable and accessible than current products available in Australia, ensuring that more Australian patients in need of these medicines can access them safely through legal access pathways and with the right medical support and supervision".

THC's medical and clinical affairs team, 'CandeoCare', will support doctors and other healthcare professionals in the prescribing of medicinal cannabis medicines, providing expert advice on the regulatory process, technical and medical aspects of medicinal cannabis patient management, and education on choice of medicine and treatment plans.

The company will supply its medicines directly to pharmacies, clinics and hospitals, meeting the Australian Government's legislated requirements for supply of medicinal cannabis, and placing it in a unique position to support new patients under the legal medicinal cannabis access schemes.

### European product distribution secured

THC has also entered into a product distribution agreement with ACA Müller, a German pharmaceuticals importer and distributor servicing more than 1,200 pharmacies across the EU including supply of EU-sourced dried flower cannabis medicine.

ACA Müller is a wholly-owned subsidiary of Franchise Cannabis Corp, which holds the first cannabis licence granted in Germany.

Under this agreement, subject to regulatory approvals, ACA Müller will distribute the company's Candeo branded TGA GMP licensed and EU GMP compliant oral solution medicines across Europe, with the first order expected to be placed by September 2020.

The agreement is initially non-binding and has a term of 18 months.

### "Strategic milestone"

Franchise Cannabis CEO Clifford Starke said: "This is a strategic milestone for the company to date which will allow us

**Price:** 0.265

**Market Cap:** \$46.63 m

### 1 Year Share Price Graph



### Share Information

**Code:** THC

**Listing:** ASX

**52 week High Low**  
0.465 0.18

**Sector:** Pharma & Biotech

**Website:** www.thcl.com.au

### Company Synopsis:

THC Global Group Ltd (ASX:THC), formerly The Hydroponics Company Ltd operates under a pharmaceutical model and is currently delivering high quality medicinal cannabis products to Australian patients through the existing access schemes.

action@proactiveinvestors.com.au

to diversify our product base into high-quality oils and position us to continue being a leader in Germany and the rest of Europe.

"Now that THC Global has achieved GMP certification, we are excited to launch a new, distinctive line of medical cannabis-derived extract products.

"We look forward to working with the THC Global team on many initiatives providing patient access to high-quality products."

This European distribution agreement complements THC Global's existing footprint for medicines export with pathways into Canada and New Zealand in place as the company commences export through 2020.

Shares have been almost 7% higher in early trade to 33 cents.

Proactive Investors facilitate the largest global investor network across 4 continents in 4 languages. With a team of analysts, journalists & professional investors Proactive produce independent coverage on 1000's of companies across every sector for private investors, private client brokers, fund managers and international investor communities.

Contact us +61 (0)2 9280 0700 [action@proactiveinvestors.com.au](mailto:action@proactiveinvestors.com.au)

### No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You understand that the Content on the Site is provided for information purposes only, and none of the information contained on the Site constitutes an offer, solicitation or recommendation to buy or sell a security. You understand that the Company receives either monetary or securities compensation for our services. We stand to benefit from any volume which any Content on the Site may generate.

You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, suitability or profitability of any particular security, portfolio of securities, transaction, investment, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including Company-related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

The Site does not, and is not intended to, provide investment, tax, accounting, legal or insurance advice, and is not and should not be construed as providing any of the foregoing. You should consult an attorney or other relevant professional regarding your specific legal, tax, investment or other needs as tailored to your specific situation.

In exchange for publishing services rendered by the Company on behalf of THC Global Group Ltd named herein, including the promotion by the Company of THC Global Group Ltd in any Content on the Site, the Company receives from said issuer annual aggregate cash compensation in the amount up to Twenty Five Thousand dollars (\$25,000).